LaVoieHealthScience Executive Panel Presents “An Unvarnished Look at J.P. Morgan Week 2020”

Distinguished Panel to Provide Health Executives with Valuable Insights into JPM Week and Ways to Maximize Your Presence in San Francisco this January

BOSTON — LaVoieHealthScience (LHS), an integrated investor and public relations consulting agency focused on advancing health and science innovations, today announced it is hosting a breakfast panel featuring senior health and investment executives titled, An Unvarnished Look at J.P. Morgan Week 2020, from 8:30 to 10:30 a.m. on Thursday, Dec. 19, 2019 at the Royal Sonesta in Cambridge, MA.

The panel is designed for CXOs, senior BD and communications executives at health companies to prepare them for and provide insights into the collection of biotech conferences held during the week of the J.P. Morgan 38th Annual Healthcare Conference, Jan. 12-16 in San Francisco. Panelists will examine the value of attending JPM Week, sharing in-depth insights based on personal experience.

Moderated by Donna LaVoie, President and CEO of LHS, the panel includes industry leaders:

  • Chris Garabedian, Chairman and CEO, Xontogeny, and Portfolio Manager, Venture for Perceptive Advisors
  • Daphne Zohar, Founder and CEO, PureTech Health
  • Milenko Cicmil, VP, Global Head of External Innovation & Partnering, Ipsen
  • Jon Civitarese, Managing Director, Investment Banking, SVB Leerink LLC

Topics to be discussed include:

  • The evolution of the J.P. Morgan Healthcare Conference
  • JPM Week 101: Who goes and why?
  • Is attending worth your company’s time and expense?
  • What is the value for large pharma companies versus smaller, private companies?
  • What is the best way to leverage JPM Week to tell an investable story that builds value?
  • Is it a good time to announce news? What kind of news matters?

Registration, breakfast and networking begin at 8:30 a.m., the panel discussion begins at 9 a.m. and a Q&A session will follow from 10 to 10:30 a.m.

About LaVoieHealthScience

LaVoieHealthScience partners with leading health and science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications, access and marketing. The firm provides public relations, investor relations and marketing consulting to build recognition and increase sales and value for health science innovations. The agency has received over 30 awards in recognition of the work it has done for its health and science industry-leading clients and was inducted in the 2018 Inc. 5000 Hall of Fame List of Fastest Growing Private Companies, ranked on the O’Dwyer’s list of 2019 Healthcare Public Relations Firms, PR Week’s list of 2019 Top Agencies and Boston Business Journal’s list of Largest Public Relations Firms in Massachusetts.

Contacts

Agency and Media:
Katie Gallagher
Account Manager, PR and Marketing
617-792-3937
kgallagher@lavoiehealthscience.com

LaVoieHealthScience Looks to the Future, Promotes Sharon Correia and Ella Deych

BOSTON/NEW YORK — August 13, 2019 — LaVoieHealthScience (LHS), an integrated investor and public relations consulting agency focused on advancing health and science innovations, today announced the promotion of two of the agency’s senior-level employees. Sharon Correia, who has been with LHS full-time since 2016, will serve as Executive Vice President, Integrated Communications and Chief Strategy Officer. Ella Deych, who joined LHS in 2015 as the agency’s first executive overseeing finance and operations, is now Vice President, Finance and Chief Operations Officer.

Sharon is an industry veteran who boasts more than twenty years of experience in health and science communications. She joined LHS in 2016 as Vice President, Integrated Communications after previously serving the agency as a senior consultant since 2010, whilst ramping up on an orphan drug communication commercialization program for Pfizer. Prior to making a full-time move to LHS, she held the role of Senior Director, Corporate Communications at Navidea Biopharmaceuticals as well as other communications and PR roles at emerging biopharmaceutical companies.

“Over the last several years, Sharon has grown with the agency — evolving her position from a hands-on executor to a senior executive capable of digging in while providing overall strategic direction on our accounts,” stated Donna LaVoie, President and CEO. “As Executive Vice President, Integrated Communications and Chief Strategy Officer, Sharon will work with me and our senior leadership team to drive strategic direction on existing and new client business.”

In 2015, Ella joined LHS from Racepoint Global, where she most recently served as the firm’s Finance Manager. Since starting at LHS as the agency’s Director of Finance and Operations, Ella has held several titles of increasing responsibility. “She has shown yearly growth and progression and has long been an important member of the senior leadership team,” said LaVoie. 

As the Vice President, Finance and Chief Operations Officer, Ella will be the senior executive tasked with overseeing the day-to-day administration and operational functions of the agency.

With new clients, new hires and the promotions of Sharon and Ella, our agency is seeing significant growth in our eighteenth year as a firm. I look forward to the future with my incredible team,” concluded LaVoie.

About LaVoieHealthScience

LaVoieHealthScience partners with leading health and science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications, access and marketing. The firm provides public relations, investor relations and marketing consulting to build recognition and increase sales and value for health science innovations. The agency has received over 30 awards in recognition of the work it has done for its health and science industry-leading clients and was inducted in the 2018 Inc. 5000 Hall of Fame List of Fastest Growing Private Companies, ranked on the  O’Dwyer’s list of 2019 Healthcare Public Relations Firms, PR Week’s list of 2019 Top Agencies and Boston Business Journal’s list of Largest Public Relations Firms in Massachusetts.

###

Agency and Media Contact:
Katie Gallagher
Account Manager, PR and Marketing
617-792-3937
kgallagher@lavoiehealthscience.co

LaVoieHealthScience Signs Eight New Clients in 1H:2019 Makes Additional Hires and Launches IR-Focused Thought Leadership Series

BOSTON & NEW YORK – July 29, 2019 – LaVoieHealthScience (LHS), an integrated investor and public relations consulting agency focused on advancing health and science innovations, today announced eight new client partnerships, additional hires and the launch of an investor relations thought leadership series. This builds on the agency’s foundational accounts with winning public and private global health companies and industry organizations.

New clients represent both public and privately held pre-commercial and commercial companies in key areas of industry growth, including cell, stem and gene therapy, CNS, rare disease, oncology, cardiovascular and retinopathy, as well as life science service providers.

LHS also began working in partnership with LeadingBiotech, a KNECT365 Informa business. The two firms will work in partnership to communicate and co-promote an exclusive event series bringing together senior-level biopharma leaders through off-the-record collaboration and dialogue meetings.

LHS’s work highlights the strength of our people and our collaborations and the importance of LHS’s proprietary methodologies including the LHS Immersion® and Blueprint plan, which forms the basis of core strategic communications and marketing programming.

“It’s all about our people and our clients – we keep them close. In our eighteenth year as a firm, I could not be more excited about our industry and its role in advancing health innovation,” said Donna L. LaVoie, President and CEO. “Working with unique and innovative clients and helping them tell their stories with a purpose, while solving complex communications challenges builds value and makes it worthwhile.”

To support a growing client roster, LHS has added Emmie Twombly as a Media Relations Specialist, Jessica Morris and Hannah Mongeon, both Account Coordinators and Harriet Ullman as a Senior Consultant, Product Communications. Emmie brings to the team media and public relations experience in the healthcare and financial sectors, placing print, online and broadcast stories. In addition to her strong strategic communications and writing background, she brings a passion for empowering women and developing thought leadership pieces. Jessica Morris and Hannah Mongeon came to LHS as part of the Mass Life Science Center Internship Challenge and bring excellent support to our teams.

Harriet Ullman brings 25 plus years of business and communications experience in the pharmaceutical industry and business consulting and was previously Vice President in the Healthcare Practice at Ogilvy PR/Feinstein Kean Healthcare. She provides clients with integrated communications support – from product communications, advocacy relationship management and media relations to strategic corporate positioning, branding and issues management.

In addition to expanding its strategic communications team this month, LHS also debuted the LHS IRalert, a thought leadership series aimed at providing updates on key IR trends for life science companies. The first alert informs life science companies on what they need to know about MiFID II.

AboutLaVoieHealthScience

LaVoieHealthScience partners with leading health and science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications, access and marketing. The firm provides public relations, investor relations and marketing consulting to build recognition and increase sales and value for health science innovations. The agency has received over 30 awards in recognition of the work it has done for its health and science industry-leading clients and was inducted in the 2018 Inc. 5000 Hall of Fame List of Fastest Growing Private Companies, as well as ranked on the O’Dwyer’s list of 2018 Healthcare Public Relations Firms.

###

Agency and Media Contact:
Katie Gallagher
Account Manager, PR and Marketing
617-792-3937
kgallagher@lavoiehealthscience.co

LaVoieHealthScience Honored with Bell Ringer Awards in Both Investor Relations and Executive Thought Leadership Categories

BOSTON — June 7, 2019 — LaVoieHealthScience (LHS), an integrated public and investor relations agency focused on advancing health and science innovations, today announced it is the recipient of two 2019 Bell Ringer Awards. The agency was awarded a Bronze Bell for Investor/Financial Relations Campaign for its work with client Newron Pharmaceuticals SpA (SWX: NWRN) and a Merit Award for Executive Thought Leadership Campaign for client Xontogeny LLC.

LHS was recognized for its investor relations work on Newron’s 2018 Research and Development (R&D) Day held this past October in New York City. An Italian-based company with a primarily European investor base, Newron sought to expand its investor presence in the United States. The LHS team crafted a comprehensive campaign to expand U.S. and global investor visibility for Newron, including creation of a scientific and investor-oriented R&D Day, strategic investor outreach and development of a U.S.-centric marketing strategy to secure both an in-person and global online audience for the event.

For client Xontogeny, LHS created a strategic executive thought leadership campaign for Chairman and CEO Chris Garabedian – an industry pioneer with more than 25 years of experience guiding and building biopharma companies to ensure development success. Building on his position as an industry leader, the campaign included an exclusive webinar series with Xconomy, strategic thought leadership placements on key conference panels and placements in business, financial and industry media outlets – totaling 16 unique pieces of coverage.

“It’s an honor to be acknowledged again this year by the PR Club of New England. This is a well-deserved recognition for the talented integrated investor and public relations team at LHS,” stated Donna L. LaVoie, President and CEO.

The Bell Ringer Awards are held annually by the PR Club of New England and celebrate the outstanding achievements of the region’s public relations and marketing professionals.

In 2018, LHS was awarded the Silver Bell Ringer Award by the PR Club of New England in the Investor/Financial Relations Campaign category. The agency has won a total of 12 Bell Ringer Awards since 2009.

AboutLaVoieHealthScience

LaVoieHealthScience partners with leading health and science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications, access and marketing. The firm provides public relations, investor relations and marketing and digital communications to build recognition and increase sales and value for health science innovations. The agency has received over 30 awards in recognition of the work it has done for its health and science industry-leading clients and was inducted in the 2018 Inc. 5000 Hall of Fame List of Fastest Growing Private Companies.

###

Agency and Media Contact:
Katie Gallagher
Account Manager, PR and Marketing
617-792-3937
kgallagher@lavoiehealthscience.com

Two LaVoieHealthScience Workshops at 2019 BIO International Convention to Highlight Strategies for Communicating with Investors, Media and Partners

Faculty includes Industry Veterans, Dr. Mark Monane, Angus McQuilken and LaVoieHealthScience Consultants

BOSTON – April 11, 2019 – This year at the 2019 BIO International Convention, to be held in Philadelphia, PA, a new workshop will feature faculty members from Monane Group Clinical Consulting LLC, international law firm McDermott Will & Emery  and LaVoieHealthScience.

This pre-conference half-day workshop session, titled Building Value for Your Assets: Communicating with Investors and Partners, takes place Sunday, June 2, 2019 from 1:00-5:00 PM. Convention registration is not needed to attend this workshop, but advanced registration is required. Register here

This interactive workshop is for mid-to-senior executives of biotechnology, pharma, medical, digital health, medical device and diagnostic companies. Learn from case studies and come away with tangible deliverables designed to jumpstart your communications program around an investable story that builds value for your assets.

Presenters include Dr. Mark Monane, Principal and Chief Medical Officer of Monane Group Clinical Consulting LLC, and Angus McQuilken, Business Development Manager, Life Sciences at McDermott Will & Emery.

As an experienced medical strategist as well as former sellside analyst and chief medical officer, Dr. Monane offers an essential Wall Street insight on story-telling that resonates, while McQuilken, former Vice President for Communications & Marketing for the Massachusetts Life Sciences Center, a state-funded life science investment agency, provides media, communications and marketing insights from working with early and mid-stage life sciences companies.

Senior consultants at LaVoieHealthScience including Donna L. LaVoie, President & CEO, Sharon Correia, SVP, Integrated Communications and Paul Sagan, AVP, Investor Relations & Corporate Communications, provide practical experience from the combined 50+ years of experience in life sciences investor, partner and media case study work.

“It’s an honor to provide key learnings to life science companies from around the globe at this pre-conference workshop with my distinguished faculty,” stated Donna L. LaVoie.

During the 2019 BIO International Convention, Donna L. LaVoie will also present the LHS Fifteen Slide Presentation® workshop on Monday, June 3, 2019 at 1:00 PM. This workshop is designed help companies tell their company story in just fifteen slides. Audience members at this session will have the unique opportunity to share their elevator pitches and receive live feedback.

About 2019 BIO International Convention

The 2019 BIO International Convention offers access to the BIO Business Forum, 3,500 companies in BIO One-on-One Partnering™, keynotes, BIO evening events, premium education sessions and 19+ session tracks.

AboutLaVoieHealthScience

LaVoieHealthScience partners with leading health and science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications, access and marketing. The firm provides public relations, investor relations and marketing and digital communications to build recognition and increase sales and value for health science innovations. The agency has received over 30 awards in recognition of the work it has done for its health and science industry-leading clients and was inducted in the 2018 Inc. 5000 Hall of Fame List of Fastest Growing Private Companies.

###

Agency and Media Contact:
Katie Gallagher
Account Manager, PR and Marketing
617-792-3937
kgallagher@lavoiehealthscience.com

LHS Enters NYC Market with Hiring of Investor Relations Health & Science Industry Expert Sharon Choe to Fuel Demand for Integrated Services Model

Firm Names IR Practice LaVoieHealthScience-IR (LHS-IR)

BOSTON – March 1, 2019 – LaVoieHealthScience (LHS), an integrated public and investor relations agency focused on advancing health and science innovations, today announced the hiring of Sharon Choe as Senior Vice President, Investor Relations & Business Development and the naming of its IR practice, LHS-IR. LHS-IR will focus on investor relations counsel, access and financial communications and Key Opinion Leader/Investor events, while the PR practice will continue to lead strategic communications engagements focused on story-telling including media and social media programming, medical/scientific communications, advocacy, spokesperson training and messaging. The firm expands its ability to provide integrated services to health and science clients worldwide.

This addition expands the firm’s presence from its strong roots in Boston/Cambridge, Massachusetts to the NYC financial market to fuel client demand for LHS’ integrated services model. Recent client wins with publicly-traded, global companies seeking US representation has accelerated LHS’ need to expand its talent. LHS’ integrated service model experienced 19 percent revenue growth over the previous fiscal year. In 2018, the firm added additional senior talent, including Doug Russell as Sr. VP & GM and Paul Sagan, AVP, Investor Relations and the promotion of Lisa DeScenza, VP, Integrated Communications.

Sharon joins the LHS team from The Ruth Group in NYC, where she has served as Senior Vice President since November 2015 until recently. Prior to her time at The Ruth Group, Sharon spent four years as Managing Director at Life Sci Advisors. As an industry veteran with extensive experience in life sciences, Sharon will use her expertise and network to expand business development for LHS, deploy best practices, hire talent and provide additional investor connections for LHS clients. Sharon will report to LHS President & CEO, Donna L. LaVoie and will be part of the Senior Leadership Team.

“We are proud to attract Sharon to our unique team of experts. Sharon will work with me and our senior team to scale the investor relations practice and build infrastructure. We will leverage our strong base of integrated public relations business, supporting leading innovators in our sector to extend our reach to the New York City financial market,” stated LaVoie.

Sharon also brings valuable experience on the buy side as a healthcare & biotech analyst at firms including UBS Asset Management, Credit Suisse Asset Management and BAM Capital LLC. “Sharon knows her way around the biotech community and Wall Street and I am certain she will play an important role with the rest of our team as we continue to add to our bench of talented specialized thinkers and executors in health and science communication,” concluded LaVoie.

“I am extremely excited by the opportunity to help lead LaVoieHealthScience’s strategic integration strategy of building a dedicated Investor Relations team to support the company’s award-winning public relations platform,” said Sharon. “I look forward to working with LHS’ talented team to advance the firm through its next phase of growth.”

About LaVoieHealthScience

LaVoieHealthScience partners with leading health and science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications and marketing. The firm provides public relations, investor relations and marketing and digital communications to build recognition and increase sales and value for health science innovations. The agency has received 50+ award in recognition of the work it has done for its health and science industry-leading clients and was inducted in the 2018 Inc. 5000 Hall of Fame List of Fastest Growing Private Companies. The firm is known for its two trademarked methodologies for its messaging/positioning program (The LHS Immersion®) as well as how to tell your company story in 15 slides (The LHS Fifteen Slide Presentation®).

LaVoieHealthScience represents leaders such as, AC Immune SA, Biotechnology Industry Organization, Carmell Therapeutics, Genosco, Landos Biopharma, LEO Science & Tech Hub, NewLink Genetics, Newron Pharmaceuticals SpA, Origenis GmbH, PathMaker Neurosystems, Propanc BioPharma, Scioto Biosciences, SIRION Biotech, Symbiotix Biotherapies, Torreya Partners, Triumvira Immunologics, Xontogeny LLC, and other emerging health and science companies.

###

Media Contact:
Katie Gallagher
Account Manager, PR and Marketing

kgallagher@lavoiehealthscience.com
617-374-8800 x109

Business Development Contact:
Sharon Choe
Senior Vice President,
Investor Relations & Business Development

schoe@lavoiehealthscience.com
857-241-7393

SIRION Biotech Names LaVoieHealthScience as Strategic Communications Agency of Record

SIRION Biotech Plans Path for US Market Expansion

Boston, MA & Martinsried, Germany – November 4, 2018 – LaVoieHealthScience (LHS), an integrated investor and public relations agency focused on advancing health and science innovations, today announced that Europe’s leading gene therapy engineer of viral vectors, SIRION Biotech GmbH, is now a client of LaVoieHealthScience.  LHS provides strategic communications programming and corporate development expertise to SIRION Biotech, helping to connect SIRION Biotech to relevant stakeholders in the U.S. life science ecosystem.  This is particularly important as SIRION Biotech plans its expansion into the U.S. market with its new Cambridge, MA site beginning January 2019.

SIRION Biotech has been engaged in research and licensing collaborations with 3 leading US biotechs in the gene therapy field since 2015. The earliest project was assisted by LaVoieHealthScience beginning in 2014, when the Germany based company with deep scientific roots in gene expression was seeking U.S. partnerships with clinical-stage gene therapy companies in order to expedite their R&D efforts.  Partnering together, LaVoieHealthScience and SIRION Biotech built its US profile, visibility and outreach efforts. 

“Partnering with LaVoieHealthScience helped us unleash our potential as a business to business provider of custom engineered viral vectors for industrial and academic research and development,” said Chief Operating Officer and Executive Director, Dieter Lingelbach.  Our planned expansion into the US market will be a strategic imperative for SIRION Biotech and we are delighted to continue working with LaVoieHealthScience as we chart our course forward.”

“We are fortunate to continue working with SIRION Biotech as Europe’s leader in the field on its next stage of growth and continue our successful partnership together, said Donna L. LaVoie, President & CEO of LaVoieHealthScience.  Dieter and founder, Chief Technology Officer, Dr. Christian Thirion have great vision to enable gene therapy and gene editing companies become more successful with the right clinical grade vector technology that will scale through manufacturing.”

About LaVoieHealthScience

LaVoieHealthScience provides public relations, investor relations, marketing and digital communications to build recognition and value for health science innovators. The agency has received more than 30 awards during the past seven years in recognition of the work it has done for its industry-leading clients and was recently inducted into the 2018 Inc. 5000 Hall of Fame list of Fastest Growing Private Companies. LaVoieHealthScience represents public and privately-held leaders such as BIO, Carmell Therapeutics, Emmaus Life Sciences, Landos Biopharma, LEO Science & Tech Hub, Life Sciences Corridor, NewLink Genetics, Newron Pharmaceuticals, Origenis GmbH, PathMaker Neurosystems, Scioto Biosciences, SIRION Biotech, Symbiotix Biotherapies, Triumvira Immunologics, XenoTherapeutics, Xontogeny LLC, and other emerging health and science companies. For more information, please visit: https://lavoiehealthscience.com/

 

About SIRION Biotech GmbH

SIRION Biotech provides custom engineering and manufacturing services of viral vectors for the life sciences and industry. Its unique focus on improving transduction efficiencies and safety make SIRION Biotech a valuable technology partner for gene and cell therapy trials. LentiBOOSTTM transduction reagent is actively used to improve hematopoitec cell transductions in clinical trials. NextGen AAV capsid evolution projects aim to improve tissue targeting and immune escape of capsids to usher in a new generation of therapeutics for international gene therapy companies.

www.sirion-biotech.com

 

###

Media Contact:
Katie Gallagher
Account Manager, PR and Marketing

kgallagher@lavoiehealthscience.com
617-374-8800 x109

 

LHS Partners with LSX World Congress USA

 
 
The LSX World Congress brought life science executives together here in Boston for strategy, investment, and partnering opportunities. As an event partner, LHS is thrilled to have participated in several key event tracks, including IPO Bootcamp, the Big Data Driven Innovation panel and two Fireside Chats.  
Fireside chat with Donna LaVoie and Pavan Cheruvu

As co-host of the IPO Bootcamp, held on Tuesday, October 9, at the Union Club in Boston, LHS was thrilled to be the investor relations consultant for executives looking for best practices for a successful IPO. The day began with an opening address from David Ethridge of PwC on the current state of the IPO market, and continued with an overview of the healthcare ECM from Jordan Saxe, Senior Managing Director at Nasdaq. A roundtable discussion on determining and defining an IPO strategy followed, with leaders from PwC, Nasdaq, Covington & Burling, Oppenheimer & Co, and LavoieHealthScience offering insights.

We are also grateful to have had SVP and General Manager, Doug Russell, moderate the LSX panel on Big Data Driven Innovation on Thursday, October 11.  Pharma and life science executives discussed how they’re harnessing the power of big data to advance drug discovery and development. Panelists included Leila Pirhaji, Founder and CEO of ReviveMed, Josh Mandel-Brehm, CEO of Camp4 Therapeutics, Gini Desphande, Founder and CEO of NuMedii, Alex de Winter, Managing Director at GE Ventures, and Janna Hutz, Senior Director, Head of Human Biology & Data Science at Eisai.  Doug led a lively discussion on the topic, with a focus on the future promise of big data in life science innovation.

Big Data Panel with Doug Russell
Fireside Chat with Paul Sagan and Brian Pereira

CEO Donna LaVoie and Paul Sagan, AVP, Investor Relations and Communications, also conducted fireside chats with pharma executives at the LSX World Congress.  Pavan Cheruvu, the CEO of Axovant, spoke with Donna LaVoie on the details of building a successful gene therapy portfolio.  Later in the evening, Paul Sagan and Brian Pereira, the CEO of Visterra, discussed the anatomy of a clinical-stage acquisition.  Pereira, whose company was recently acquired by the Pharmaceutical Co., Ltd of Japan, offered a timely and relevant perspective on the topic. 

The two day conference offered many interesting and engaging panels as well as great networking opportunities. LHS is happy to have partnered with LSX this year for a successful World Congress.

LaVoieHealthScience to Co-Host the IPO Bootcamp at the LSX World Congress USA

Our agency is excited to be co-hosting the IPO Bootcamp at the LSX World Congress on October 9, 2018 in Boston, MA.

The IPO Bootcamp is a full day immersive workshop focused on effectively navigating the nuances of an initial public offering.  In addition to LHS, this bootcamp is co-hosted with Covington & Burling LLP, Nasdaq, and Oppenheimer & Co, Inc.  LHS will provide personalized expertise on public relations, investor relations, and corporate communications strategy to nine attending CEOs.

Executives planning to take their company public have the opportunity for 1:1 sessions with co-hosts to explore individualized mechanics, ideas, and best practices throughout the IPO process.  Discussions will be thorough and transparent, offering companies quality insights on the ins and outs of a successful IPO.

Discussions include:

  • Keynote address: the current state of capital markets
  • Anatomy of an IPO: Back to back case study discussions of IPOs
  • Legal preparations
  • Financial PR and communications
  • Regulatory requirements and IPO checklists

The IPO Bootcamp will take place one day prior to the LSX World Congress USA conference, which offers education, strategies, and solutions for life science executives to grow their business. The event will be held at the Union Club at 8 Park St, Boston, MA.

LaVoieHealthScience Promotes Sharon Correia to Senior Vice President, Integrated Communications

Boston, MA – September 5, 2018 – LaVoieHealthScience (LHS), an integrated investor and public relations agency focused on advancing health and science innovations, today announced the promotion of Sharon Correia to Senior Vice President, Integrated Communications.

Ms. Correia joined LHS in 2016 as Vice President, Integrated Communications from Navidea Biopharmaceuticals, where she was Sr. Director of Corporate Communications. An industry veteran with more than two decades of health and science communications experience spanning agency, publicly-traded and private companies, Sharon designs and executes programs that resonate from development phase through commercialization. Sharon has demonstrated alignment with LHS’s core values and a fast-moving, collaborative culture focused on problem solving.

“I am delighted to celebrate Sharon’s success at LHS and the engagement and experience that she brings to our people, clients and community. In her new role, Sharon continues to report to me and works with the senior leadership team on client strategy, execution, team building and high-level programming,” stated Donna L. LaVoie, President & CEO of LaVoieHealthScience.

Sharon brings industry-tested integrated communications experience spanning public and medical communications, investor communications and professional advocacy relations. She’s led communications teams for multiple new drug applications in the US and EU, global product launches as well as several sNDA’s, IPOs and key data dissemination at medical meetings.

“I am truly excited to continue to contribute my expertise to the well-regarded group of specialized thinkers at LHS who are solving client problems and helping them advance health and science innovation,” said Correia. “Each and every LHS client provides our team with unique and dramatic perspectives on how creative story-telling creates competitive advantage.”

About LaVoieHealthScience
LaVoieHealthScience partners with leading health and science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications and marketing. The firm provides public relations, investor relations and marketing and digital communications to build recognition and increase sales and value for health science innovations. The agency has received over 30 awards over the past seven years in recognition of the work it has done for its health and science industry-leading clients and was inducted in the 2018 Inc. 5000 Hall of Fame List of Fastest Growing Private Companies. LaVoieHealthScience represents leaders such as, Emmaus Life Sciences, Landos Biopharma, LEO Science & Tech Hub, Life Sciences Corridor, NewLink Genetics, Newron Pharmaceuticals, Origenis GmbH, PathMaker Neurosystems, Scioto Biosciences, Symbiotix Biotherapies, Triumvira Immunologics, XenoTherapeutics, Xontogeny LLC, and other emerging health and science companies.

###

Media Contact:
Katie Gallagher
Account Manager, PR and Marketing
kgallagher@lavoiehealthscience.com
617-374-8800 x109